Lionco Pharmaceutical Group Co.,Ltd. (603669.SS)
CNY 6.69
(-3.04%)
CNY 6.69
(-3.04%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 196.83 Million CNY | -31.95% |
| 2022 | 289.26 Million CNY | -60.93% |
| 2021 | 740.32 Million CNY | -26.04% |
| 2020 | 1 Billion CNY | -38.78% |
| 2019 | 1.63 Billion CNY | -2.06% |
| 2018 | 1.66 Billion CNY | 66.1% |
| 2017 | 1 Billion CNY | 110.01% |
| 2016 | 478.58 Million CNY | -13.09% |
| 2015 | 550.64 Million CNY | -4.47% |
| 2014 | 576.4 Million CNY | 16.62% |
| 2013 | 494.24 Million CNY | 5.54% |
| 2012 | 468.27 Million CNY | 72.45% |
| 2011 | 271.54 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 63.84 Million CNY | -16.22% |
| 2024 Q1 | 76.2 Million CNY | 65.06% |
| 2024 Q3 | 88.78 Million CNY | 40.27% |
| 2023 Q1 | 73.3 Million CNY | 92.63% |
| 2023 FY | 196.83 Million CNY | -31.95% |
| 2023 Q4 | 46.16 Million CNY | 22.31% |
| 2023 Q3 | 37.74 Million CNY | -4.73% |
| 2023 Q2 | 39.61 Million CNY | -45.95% |
| 2022 Q4 | 38.05 Million CNY | -25.28% |
| 2022 Q3 | 50.92 Million CNY | -31.44% |
| 2022 Q2 | 74.28 Million CNY | -41.05% |
| 2022 Q1 | 126 Million CNY | 45.91% |
| 2022 FY | 289.26 Million CNY | -60.93% |
| 2021 Q1 | 273.96 Million CNY | 18.6% |
| 2021 Q4 | 86.35 Million CNY | -50.95% |
| 2021 Q3 | 176.04 Million CNY | -13.69% |
| 2021 Q2 | 203.96 Million CNY | -25.55% |
| 2021 FY | 740.32 Million CNY | -26.04% |
| 2020 Q3 | 296.22 Million CNY | 38.36% |
| 2020 FY | 1 Billion CNY | -38.78% |
| 2020 Q2 | 214.1 Million CNY | -17.55% |
| 2020 Q1 | 259.67 Million CNY | -38.7% |
| 2020 Q4 | 231 Million CNY | -22.01% |
| 2019 Q4 | 423.59 Million CNY | 13.16% |
| 2019 Q2 | 471.89 Million CNY | 29.23% |
| 2019 Q1 | 365.16 Million CNY | -25.1% |
| 2019 Q3 | 374.34 Million CNY | -20.67% |
| 2019 FY | 1.63 Billion CNY | -2.06% |
| 2018 Q4 | 487.55 Million CNY | 33.48% |
| 2018 FY | 1.66 Billion CNY | 66.1% |
| 2018 Q3 | 365.27 Million CNY | -25.62% |
| 2018 Q2 | 491.09 Million CNY | 50.88% |
| 2018 Q1 | 325.49 Million CNY | -23.92% |
| 2017 Q1 | 121.37 Million CNY | -22.75% |
| 2017 Q2 | 212.03 Million CNY | 74.7% |
| 2017 Q3 | 243.84 Million CNY | 15.0% |
| 2017 Q4 | 427.82 Million CNY | 75.45% |
| 2017 FY | 1 Billion CNY | 110.01% |
| 2016 Q1 | 102.82 Million CNY | -42.76% |
| 2016 FY | 478.58 Million CNY | -13.09% |
| 2016 Q2 | 105.98 Million CNY | 3.07% |
| 2016 Q3 | 112.67 Million CNY | 6.31% |
| 2016 Q4 | 157.11 Million CNY | 39.44% |
| 2015 Q4 | 179.64 Million CNY | 42.68% |
| 2015 Q3 | 125.9 Million CNY | -11.94% |
| 2015 Q2 | 142.98 Million CNY | 40.02% |
| 2015 Q1 | 102.11 Million CNY | -45.48% |
| 2015 FY | 550.64 Million CNY | -4.47% |
| 2014 Q2 | 157.77 Million CNY | 46.88% |
| 2014 FY | 576.4 Million CNY | 16.62% |
| 2014 Q4 | 187.29 Million CNY | 51.15% |
| 2014 Q1 | 107.42 Million CNY | 0.0% |
| 2014 Q3 | 123.91 Million CNY | -21.46% |
| 2013 FY | 494.24 Million CNY | 5.54% |
| 2012 FY | 468.27 Million CNY | 72.45% |
| 2011 FY | 271.54 Million CNY | 0.0% |